CSPC Megalith Biopharmaceutical Co.,Ltd. clinical trials

A subsidiary of CSPC Pharmaceutical Group Limited

The registry lists 38 studies whose lead sponsor is CSPC Megalith Biopharmaceutical Co.,Ltd.. 37 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 38 of 38. All CSPC Pharmaceutical Group Limited studies →

• Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and AboveNot yet recruitingNCT07892989Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell CarcinomaRecruitingNCT07254585Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07879911Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsNot yet recruitingNCT07857135Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube CancersRecruitingNCT07708753Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid TumorsNot yet recruitingNCT07833735Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian CancerRecruitingNCT07714668Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYH2092 Injection in Healthy ParticipantsNot yet recruitingNCT07776041Phase 1

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingNCT07761286Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCCNot yet recruitingNCT07758621Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingNCT07750041Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid TumorsRecruitingNCT07744763Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase II Clinical Trial Evaluating the Efficacy and Safety of SYS6026 Injection in Participants With HPV16 or 18-related High-grade Cervical Squamous Intraepithelial LesionsNot yet recruitingNCT07702656Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid TumorsNot yet recruitingNCT07684261

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）RecruitingNCT06927986Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT07672223Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Clinical Study of SYS6023 Combination Therapy for Advanced Breast CancerRecruitingNCT07597629Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）Not yet recruitingNCT07633873Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid TumorsNot yet recruitingNCT07622225Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYS6051 in Subjects With Advanced Solid TumorsNot yet recruitingNCT07591285Phase 1

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCNot yet recruitingNCT07376382Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial CarcinomaNot yet recruitingNCT07526792Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase ⅢNot yet recruitingNCT07442565Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07417735Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid TumorsRecruitingNCT07415863Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast CancerNot yet recruitingNCT07406542Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6002 vs PADCEV in Patients With Advanced Urothelial CarcinomaNot yet recruitingNCT07374549Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and AboveNot yet recruitingNCT07354659Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung CancerNot yet recruitingNCT07256509Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.Not yet recruitingNCT07251062Phase 2/3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical CancerNot yet recruitingNCT07230626Phase 3

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCCNot yet recruitingNCT06989671Phase 2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Clinical Study of SYS6023 in Patients With Advanced Solid TumorsRecruitingNCT07110883Phase 1

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Evaluation of SYS6005 in Patients With Advanced Malignant TumorRecruitingNCT06958679Phase 1

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• A Study of SYS6040 for Injection in Patients With Advanced Solid TumorsRecruitingNCT06970795Phase 1

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or MoreNot yet recruitingNCT06954818Phase 1

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid TumorsNot yet recruitingNCT06775236Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.

• Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid TumorsActive, not recruitingNCT07122063Phase 1/2

  Sponsor listed in the registry: CSPC Megalith Biopharmaceutical Co.,Ltd.